Alimera Sciences (ALIM) News Today

Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 617,100 shares, a growth of 169.1% from the June 30th total of 229,300 shares. Based on an average daily volume of 324,600 shares, the short-interest ratio is presently 1.9 days.

StockNews.com started coverage on Alimera Sciences in a report on Friday. They set a "hold" rating on the stock.

Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 229,300 shares, an increase of 142.1% from the June 15th total of 94,700 shares. Based on an average trading volume of 312,200 shares, the short-interest ratio is presently 0.7 days.

StockNews.com assumed coverage on shares of Alimera Sciences in a research note on Thursday. They set a "hold" rating on the stock.

Alliance Global Partners restated a "neutral" rating on shares of Alimera Sciences in a research report on Tuesday.

HC Wainwright lowered Alimera Sciences from a "buy" rating to a "neutral" rating in a research report on Tuesday.

Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 127,000 shares, a growth of 22.2% from the May 15th total of 103,900 shares. Based on an average trading volume of 98,200 shares, the days-to-cover ratio is presently 1.3 days.

Alimera Sciences, Inc. (NASDAQ:ALIM - Free Report) - Analysts at HC Wainwright decreased their Q3 2024 earnings estimates for Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings per share of (

HC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Alimera Sciences in a report on Thursday.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $23.01 million during the quarter, compared to analyst estimates of $23.72 million. Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. During the same period in the previous year, the firm posted ($0.71) EPS.

Alimera Sciences (NASDAQ:ALIM) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591841)

StockNews.com cut Alimera Sciences from a "buy" rating to a "hold" rating in a report on Tuesday.

StockNews.com upgraded Alimera Sciences from a "hold" rating to a "buy" rating in a research report on Monday.

Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 108,800 shares, a growth of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is presently 1.3 days.

StockNews.com lowered shares of Alimera Sciences from a "buy" rating to a "hold" rating in a report on Friday.

StockNews.com upgraded shares of Alimera Sciences from a "hold" rating to a "buy" rating in a research note on Thursday.

Maxim Group assumed coverage on Alimera Sciences in a research report on Monday. They issued a "buy" rating and a $10.00 target price for the company.

Alimera Sciences (NASDAQ:ALIM) Stock Crosses Above 200-Day Moving Average of $3.53

Alimera Sciences (NASDAQ:ALIM - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.09). The business had revenue of $26.31 million for the quarter, compared to analysts' expectations of $25.10 million. During the same period in the previous year, the company earned ($0.54) earnings per share.